Dr. Norbert Gleicher, MD, FACOG, FACS, is Chief Scientist and Medical Director at the Center for Human Reproduction in New York, NY.
After preclinical years in Vienna, Austria, he switched to Tel Aviv University’s Sackler School of Medicine in Israel, where he graduated. He completed a fellowship in reproductive immunology and a residency in Obstetrics and Gynecology Mount Sinai Medical Center in NYC, where he received the Dr. Solomon Silver Award for “that younger member of The Mount Sinai Hospital and Medical Center staff who best exemplifies the ability to apply the advance in research to the practice of clinical medicine”.
Upon graduation, he became Head of the Division of Reproductive Immunology, and Coordinator of student as well as residency programs in Ob/Gyn. Two years later he moved for 10 years to Chicago as Chairman of Obstetrics and Gynecology at Mount Sinai Hospital and Professor of Obstetrics and Gynecology and Immunology/Microbiology at Rush Medical College. As of 1990, he concentrated on the Center for Human Reproduction (CHR) turning it into one of the world’s best-known IVF centers and held appointments at Chicago Medical School, New York University School of Medicine and Yale University School of Medicine and, currently, is Guest Investigator at Rockefeller University and Professor (Adj.) at Medical University Vienna.
Dr. Gleicher published over 400 peer-reviewed scientific papers and served as founding Editor-in-Chief of the American Journal of Reproductive Immunology (AJRI), and the Journal of Assisted Reproduction and Genetics (JARG). In 1991, he was awarded Austria’s highest cultural award, the Austrian Honor Cross for Science and Art. In 2009, in recognition of his contributions to advancements in the in vitro fertilization field, Dr. Gleicher was invited to give the prestigious Patrick Steptoe Memorial Lecture to the British Fertility Society.
Realizując projekt „Internacjonalizacja i rozwój innowacyjności aplikacji mobilnej wspierającej płodność oraz starania o ciążę” korzystamy z dofinansowania o wartości 120 522,74 EUR otrzymanego od Norwegii (wartość projektu 641 550 PLN). Celem projektu jest opracowanie i wdrożenie w aplikacji mobilnej nowatorskich rozwiązań wspierających starania o ciążę, a także profilaktykę niepłodności oraz wprowadzenie produktu na nowe rynki.